Comorbidity and age affect treatment policy for cervical cancer: a population-based study in the south of the Netherlands, 1995-2004

Objective. The aim of this study was to estimate the effects of age and comorbidity on the choice of treatment modalities and prognosis for patients with cervical cancer. Methods. All patients with cervical cancer newly diagnosed between 1995 and 2004 (n = 775) were selected from the population-based Eindhoven Cancer Registry. Time trends in treatment modalities and differences in treatment between older and younger patients, and those with and without comorbidity were evaluated. Results. Older patients with FIGO Stages IB-IIA, elderly and those with comorbidity underwent less surgery. In multivariate survival analysis, age had independent prognostic value. For patients with FIGO Stages 1132, IIB-IVA, age affected the choice of chemoradiation significantly. According to multivariate survival analysis, comorbidity and FIGO stage were independent prognostic factors. Conclusion. Older patients with cervical cancer and those with comorbidity were treated less aggressively. Because of the ever-increasing role of comorbidity in clinical decision-making for increasingly older patients in the near future, development of age-specific guidelines incorporating levels and management of specific comorbidity seems warranted.

Cervical cancer; Comorbidity; Radical hysterectomy; Radiotherapy; Chemoradiation

[1] Comprehensive Cancer Centres. http://www.ikcnet.nl/. retrieved 6-2-2007.

[2] Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V. et al.: “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide”. J. Pathol., 1999, 189, 12.

[3] Franco E.L., Duarte-Franco E., Ferenczy A.: “Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection”. CMAJ, 2001, 164, 1017.

[4] Plummer M., Herrero R., Franceschi S., Meijer C.J., Snijders P., Bosch F.X. et al.: “Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study”. Cancer Causes Control, 2003, 14, 805.

[5] Trimbos J.B.: “Gynaecologische Oncologieklapper”. 2nd ed. Leiden, the Netherlands: Working Group for Gynecological Oncology; 1995.

[6] Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E. et al.: “Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer”. N. Engl. J. Med., 1999, 340, 1137.

[7] Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler W.C. Jr., et al.: “Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in Stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study”. J. Clin. Oncol., 1999, 17, 1339.

[8] Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs C.L. III, et al.: “Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky Stage IB cervical carcinoma”. N. Engl. J. Med., 1999, 340, 1154.

[9] Peters W.A. III, Liu P.Y., Barrett R.J., Stock R.J., Monk B.J., Berek J.S. et al.: “Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix”. J. Clin. Oncol., 2000, 18, 1606-.

[10] Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A. et al.: “Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer”. N. Engl. J. Med., 1999, 340, 1144.

[11] van der Zee J., Gonzalez G.D.: “The Dutch Deep Hyperthermia Trial: results in cervical cancer”. Int. J. Hyperthermia, 2002, 18, 1.

[12] Working Group Gynaecologic Oncology. http://www.oncoline.nl. retrieved 2007.

[13] Brooks S.E., Chen T.T., Ghosh A., Mullins C.D., Gardner J.F., Baquet C.R.: “Cervical cancer outcomes analysis: impact of age, race, and comorbid illness on hospitalizations for invasive carcinoma of the cervix”. Gynecol. Oncol., 2000, 79, 107.

[14] Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R.: “A new method of classifying prognostic comorbidity in longitudinal studies: development and validation”. J. Chronic. Dis., 1987, 40, 373.

[15] Hermanek P., Hutter R., Sobin L., Wagner G., Wittekind C. (eds.). TNM Atlas. 4th edition, Berlin, UICC, Springer-Verlag, 1997.

[16] Ederer F., Axtell L.M., Cutler S.J.: “The relative survival rate: a statistical methodology”. Natl. Cancer Inst. Monogr., 1961, 6, 101.

[17] Yamashita H., Nakagawa K., Tago M., Shiraishi K., Nakamura N., Ohtomo K. et al.: “Comparison between conventional surgery and radiotherapy for FIGO Stage I-II cervical carcinoma: a retrospective Japanese study”. Gynecol. Oncol., 2005, 97, 834.

[18] Landoni F., Maneo A., Colombo A., Placa F., Milani R., Perego P., et al.: “Randomised study of radical surgery versus radiotherapy for Stage Ib-IIa cervical cancer”. Lancet, 1997, 350, 535.

[19] Goodheart M., Jacobson G., Smith B.J., Zhou L.: “Chemoradiation for invasive cervical cancer in elderly patients: outcomes and morbidity”. Int. J. Gynecol. Cancer, 2008, 26, 95.

[20] Wright J.D., Gibb R.K., Geevarghese S., Powell M.A., Herzog T.J., Mutch D.G. et al.: “Cervical carcinoma in the elderly: an analysis of patterns of care and outcome”. Cancer, 2005, 103, 85.

[21] Yellen S.B., Cella D.F., Leslie W.T.: “Age and clinical decision making in oncology patients”. J. Natl. Cancer Inst., 1994, 86, 1766.

[22] Newcomb P.A., Carbone P.P.: “Cancer treatment and age: patient perspectives”. J. Natl. Cancer Inst., 1993, 85, 1580.

[23] Monk B.J., Tian C., Rose P.G., Lanciano R.: “Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials”. Gynecol. Oncol., 2007, 105, 427.

[24] Houterman S., Verheij C.D.G.W., Jansen-Heijnen M.L.G. et al.: “Validation study on comorbidity in women with breast cancer diagnosed between 1995 and 1999 (internal report)”. Eindhoven: Eindhoven Cancer Registry, 2003.

[25] Signaleringscommissie Kanker van K.W.F. Kankerbestrijding. Kanker in Nederland; Trends, prognoses en implicaties voor zorgvraag. Oisterwijk: Drukkerij van den Boogaard, 2004.